Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Interest Income

Income earned on cash, deposits, and investments held by the company.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Interest Income · Q4 FY2026 · quarter ended Sep 2026

Interest income growth accelerates

Q4 FY2026 interest income of $14.37M rose 58.7% year over year, ahead of the +55.2% change in trailing-twelve-month interest income. Sequentially, it fell 15.2% from the prior quarter. Over 3 fiscal years it compounded at +55.8% a year.

Context

  • Interest income amounted to 12.8% of revenue in FY2026, up 8.3 pp from a year earlier.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +58.7% holds above the trailing-twelve-month pace of +55.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$14.37M-15.2% QoQ
Last fiscal yearSep 2026
$57.86M+55.2% YoY
LTMSep 2026
$57.86M+55.2% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.7%——
1 year+55.2%——
3-year CAGR+55.8%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2026
57.86M USD
Year-over-year change
+55.2%
4-year CAGR
+84.1%

Interest Income vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +55.2% is the highest of 6, against a peer median of -11.7%.
  • Interest income amounts to 12.8% of revenue for ARWR, versus a peer median of 7.9%.
ARWR Competitors
Interest Income for ARWR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$110.05M USD-7.8%+65.0%2.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$89.99M USD-11.7%+56.9%9.4%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$57.86M USD+55.2%+55.8%12.8%
WVEWave Life Sciences Ltd.LTM Mar 2026$12.89M USD+22.8%—18.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$9.27M USD-47.9%+57.6%20.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€852.58K EUR-60.2%+176.5%6.3%
SLNSilence Therapeutics plcLTM Mar 2026$0 USD—+148.8%0.0%
Peer median (excluding ARWR) —-11.7%+65.0%7.9%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.